![](\"https:\/\/mms.businesswire.com\/media\/20260513072159\/en\/2804079\/5\/ONJCRI_researchers.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260513072159\/en\/2804077\/4\/OliviaNJCRI_Logo.jpg\"){kind=logo}
<\/a><\/a>\nThe institute (ONJCRI) wants the world to imagine\u2014and secure\u2014a future where cancer treatments are more targeted and less harmful. Cancer patients often experience life-altering side effects as a result of cancer treatment. More precise therapies better distinguish cancer cells from healthy tissue, reducing this quality-of-life burden.<\/p>
\nBy harnessing Qumulo\u2019s scalable data platform, cancer researchers can analyze massive volumes of genomic data with speed and precision, helping them transform raw data into more personalized treatments. Behind every data point is a cancer patient, their cancer journey and the next research breakthrough.<\/p>
\n\u201cAt Qumulo, we believe data infrastructure should do more than move files. It should move the world forward,\u201d said Michelle Palleschi, Chief Operating Officer at Qumulo. \u201cWe\u2019re proud to have the institute as a customer and to be reminded that the work we do matters. When data flows without friction, researchers can focus on saving and improving lives.\u201d<\/p>
\nThe momentum behind research at ONJCRI, based in Melbourne, Australia, has never been stronger. In the past year:<\/p>
- \n
- \nInstitute scientists uncovered a striking link<\/a> between the nervous system and gastrointestinal cancer, raising the prospect of repurposing existing migraine medications to slow tumor growth.<\/li>\n
- \nONJCRI scientists, in partnership with the Walter and Eliza Hall Institute of Medical Research, identified<\/a> that the TAK1 gene acts as a \"safety switch\", shielding cancer cells from immune system attacks. By switching off the gene, the breakthrough potentially opens the way for more efficient immunotherapy treatments.<\/li>\n
- \nA rare-cancer clinical trial<\/a> \u2014 spanning rural and urban sites across Australia and New Zealand \u2014 demonstrated that a novel immunotherapy combination induced remission in patients with advanced disease who previously had almost no treatment options.<\/li>\n<\/ul>
\nResearchers also engineered next generation nanoparticles<\/a> that deliver cancer therapies with far greater precision. And the institute's CRISPR platform, MAGEC,<\/a> has produced over 400 animal models of disease, distributed to hundreds of laboratories worldwide, and has fueled more than 100 published studies.<\/p>
\nData Powers Discovery<\/b><\/p>
\nScience at this scale generates an extraordinary volume of data \u2014 genomic sequences, high-resolution tumor images, clinical trial records, and real-time imaging from scanners. Qumulo provides the unstructured data infrastructure that keeps this information flowing seamlessly across ONJCRI's advanced research platforms. When researchers need answers fast, whether tracking cancer cells with genetic barcodes or modeling nanoparticle delivery in live animals, reliable, scalable data management is the foundation on which everything is built.<\/p>
\nThroughout May, ONJCRI invites individuals, businesses, and organizations to imagine <\/i>a better future for cancer treatment and to act. Donations made during the Imagine Appeal directly support the institute's research programs, discovering more precise and gentler cancer therapies. Qumulo encourages its own community \u2014 customers, partners, and employees \u2014 to consider supporting this remarkable work.<\/p>
\nTo donate or learn more about the Imagine Appeal, visit https:\/\/imagine.org.au<\/a><\/p>
\nTo learn more about this partnership, please read the full case study here<\/a>.<\/p>
\nAbout Qumulo<\/b><\/p>
\nQumulo is the only seven-time Leader in the Gartner Magic Quadrant for Distributed File and Object Storage and the foremost provider of cloud data platforms. With exabytes under management and more than 1,000 production customers, Qumulo is trusted by Fortune 500 companies and global enterprises to manage, store, curate, and protect their data, unlocking new possibilities and driving innovation across diverse industries. For more information, visit www.qumulo.com<\/a>.<\/p>
- \nONJCRI scientists, in partnership with the Walter and Eliza Hall Institute of Medical Research, identified<\/a> that the TAK1 gene acts as a \"safety switch\", shielding cancer cells from immune system attacks. By switching off the gene, the breakthrough potentially opens the way for more efficient immunotherapy treatments.<\/li>\n